Anderman Jonathan 4/A

What Happened Jonathan Anderman, General Counsel of Compass Therapeutics (CMPX), purchased 25,000 shares in an open-market transaction on April 29, 2026 at $1.89 per share, for a total cost of $47,250. The Form 4 was amended on April 30, 2026 to correct the transaction code to P (purchase).

Key Details

• Transaction date and price: 2026-04-29, 25,000 shares @ $1.89 each (total $47,250).
• Filing: Amended Form 4 filed 2026-04-30 to correct the transaction code from A to P; all other information unchanged.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The filing discloses 150,000 unvested restricted stock units (RSUs) granted January 2, 2026; each RSU equals one contingent share and vests in four equal annual installments with the first vesting on January 2, 2027.
• Timeliness: Amendment was to correct reporting; the transaction reporting does not indicate a late filing beyond the correction.

Context This was an outright open-market purchase (transaction code P). Purchases by insiders are often viewed as more informative than sales because they represent capital deployed by insiders, but filings do not state motive. The RSUs noted are unvested and subject to service-based vesting; they are separate from this open-market purchase.